Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMOSA: Biomarkers for Methylphenidate in ADHD Children
NCT04272021Phase 4Unknown
- Sponsor
- IRCCS Eugenio Medea
- Start
- Apr 2018
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by IRCCS Eugenio Medea. Primary endpoint: ADHD Rating Scale. Status: unknown.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04272021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272021.